Dr. Toby Maher
of the Keck School of Medicine will give oral presentations for
both scientific abstracts on oral nalbuphine extended release for
chronic cough in IPF
NEW
HAVEN, Conn., May 2, 2023
/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a
clinical-stage biopharmaceutical company developing the
investigational therapy Haduvio™ (oral nalbuphine ER) for the
treatment of chronic cough in adults with idiopathic pulmonary
fibrosis (IPF) and other chronic cough indications, today announced
data will be presented from two scientific abstracts on the phase 2
CANAL trial in IPF chronic cough at the ATS
2023 International Conference, organized by the American
Thoracic Society, being held in Washington, D.C. from May 19-24. The oral presentations will take place
on May 22.
![Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.) Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)](https://mma.prnewswire.com/media/1504281/Trevi_Therapeutics_Logo.jpg)
Presentation: Session B17: Emerging Data on Disease
and Symptom Based Therapeutics for Patients with IPF
Abstract: Efficacy of Oral Nalbuphine Extended Release in
Patients with Idiopathic-Pulmonary-Fibrosis-Related Chronic Cough:
A Phase 2 Study
Presentation: May 22,
10:00 a.m. – 10:12 a.m.
ET
Presenter: Dr. Toby
Maher, MD, Professor of Medicine and Director of
Interstitial Lung Disease at Keck School of Medicine, University of Southern California
Presentation: Session B17: Emerging Data on Disease
and Symptom Based Therapeutics for Patients with IPF
Abstract: The Effect of Oral Nalbuphine
Extended Release on Patient-reported Outcome Measures in Patients
with Idiopathic-Pulmonary-Fibrosis-Related Chronic Cough
Presentation: May 22,
10:12 a.m. – 10:24 a.m. ET
Presenter: Dr. Toby
Maher, MD, Professor of Medicine and Director of
Interstitial Lung Disease at Keck School of Medicine,
University of Southern
California
Registration details: https://conference.thoracic.org/
About Chronic Cough in Idiopathic Pulmonary
Fibrosis
IPF is a serious, end-of-life disease. Chronic
cough is one of the most common symptoms of IPF and has a
significant impact on quality of life in these patients. There are
estimated to be 140,000 IPF patients in the US and more than 1
million patients ex-US, where up to 85% of these patients
experience chronic cough. There are no approved therapies for the
treatment of chronic cough in IPF and the cough often isn't
affected by antitussive therapy. Patients with chronic cough in IPF
can cough up to 1,500 times per day, leading to increased feelings
of fear and stress as it causes shortness of breath. Coughing
spells or episodes lead to significant fatigue, an urge to breathe,
low levels of oxygen in blood, and some patients also experience
loss of bladder control. The social impact of chronic cough in IPF
is increased because of limited exercise ability, reduced walking
distance, and the need to use additional oxygen. Chronic cough in
IPF may be an early clinical marker of disease activity that could
potentially help to identify patients at high risk of progression
and predict time to death or lung transplant. In addition, chronic
cough in IPF may also contribute to enhanced activation of
profibrotic mechanisms and disease worsening.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing Haduvio, an investigational therapy in an oral
extended-release formulation of nalbuphine, for the treatment of
chronic cough in IPF and other chronic cough indications. Haduvio
is a mixed ĸ-opioid receptor agonist and µ-opioid receptor
antagonist that works both centrally and peripherally. The ĸ and µ
receptors are known critical mediators of cough. Parenteral
nalbuphine has been approved and marketed for over 20 years for the
treatment of acute pain indications and is not scheduled by the DEA
in the United States or by regulatory authorities in most
of Europe. Trevi intends to propose Haduvio as the trade name
for nalbuphine ER. Its safety and efficacy have not been evaluated
by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and
follow Trevi on Twitter and LinkedIn.
Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-announces-two-presentations-on-the-phase-2-canal-data-at-the-ats-2023-international-conference-301812888.html
SOURCE Trevi Therapeutics, Inc.